GeneOne Life Science, Inc. (KRX:011000)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,015.00
+48.00 (2.44%)
Feb 5, 2026, 3:30 PM KST

GeneOne Life Science Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
985.851,1809,11113,26122,31062,432
Short-Term Investments
1,020566.19406.632,34285,09428,086
Trading Asset Securities
701-470.79---
Cash & Short-Term Investments
2,7071,7469,98845,603107,40490,518
Cash Growth
-25.35%-82.52%-78.10%-57.54%18.65%417.94%
Accounts Receivable
3,9767,1826,6248,9807,4387,408
Other Receivables
124.71,050948.441,5981,975374.05
Receivables
4,3798,3107,65210,65910,0918,401
Inventory
15,40116,51114,89714,86410,6888,299
Prepaid Expenses
898.621,5421,2251,145706.461,226
Other Current Assets
456.65525.52811793.085,744315.08
Total Current Assets
23,84328,63534,57373,063134,633108,760
Property, Plant & Equipment
97,780117,730111,399144,369110,38222,427
Long-Term Investments
22.1218.550.39147.49437.33710.58
Other Intangible Assets
197.35189.96385.99563.91643.1683.11
Long-Term Deferred Tax Assets
20.7121.7113.2836.4214.24154.29
Other Long-Term Assets
3,6824,7394,5864,6874,7353,750
Total Assets
125,544151,334151,008222,867250,857136,571
Accounts Payable
20,22520,17610,0667,49317,5316,881
Accrued Expenses
4,9434,9101,9712,3271,173931.56
Short-Term Debt
8,0183,3772,40512,2469,75415,634
Current Portion of Leases
2,4562,8952,3961,9111,5431,337
Other Current Liabilities
12,33511,1476,0299,8584,75811,920
Total Current Liabilities
47,97642,50622,86733,83634,75936,705
Long-Term Debt
17,04316,3736,273---
Long-Term Leases
2,8684,4806,0855,5097,103794.09
Pension & Post-Retirement Benefits
267.524.12,096-820.3588.92
Long-Term Deferred Tax Liabilities
147.69154.83323.98457.33144.32-
Other Long-Term Liabilities
1,8842,1921,8721,5941,524473.64
Total Liabilities
70,18665,72939,51841,39544,35038,062
Common Stock
85,41080,03978,47477,75277,47944,771
Additional Paid-In Capital
223,175217,579215,555214,299209,871117,319
Retained Earnings
-300,563-264,848-216,231-137,155-98,241-81,567
Treasury Stock
-2,955-2,955-2,955-2,955-2,955-2,371
Comprehensive Income & Other
50,29255,79136,64729,53120,35320,357
Shareholders' Equity
55,35885,605111,489181,471206,50798,509
Total Liabilities & Equity
125,544151,334151,008222,867250,857136,571
Total Debt
30,38527,12617,16019,66618,40017,766
Net Cash (Debt)
-27,678-25,379-7,17125,93789,00472,752
Net Cash Growth
----70.86%22.34%2333.27%
Net Cash Per Share
-338.07-319.41-92.24334.731198.841205.09
Filing Date Shares Outstanding
85.279.8378.2677.5477.2766.9
Total Common Shares Outstanding
85.279.8378.2677.5477.2766.9
Working Capital
-24,133-13,87011,70539,22799,87572,055
Book Value Per Share
649.741072.351424.522340.292672.551472.58
Tangible Book Value
55,16185,415111,103180,907205,86497,826
Tangible Book Value Per Share
647.431069.971419.592333.022664.231462.37
Land
3,5023,7203,1394,0813,8173,503
Buildings
72,50776,19263,3741,4031,3311,328
Machinery
56,30555,31848,59915,19911,7759,776
Construction In Progress
---104,66178,28311,489
Leasehold Improvements
17,03716,41414,86713,13912,1246,739
Source: S&P Global Market Intelligence. Standard template. Financial Sources.